22,135,656
Vote Records
28,570
Companies
12,092
Funds
3,981
Managers

Home › Companies › RHYTHM PHARMACEUTICALS INC. › 2024-2025

RHYTHM PHARMACEUTICALS INC. 2024-2025 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and RHYTHM PHARMACEUTICALS INC.’s Form 8-K, filed June 26, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 12Ballot items
  • 292Asset managers, any item
  • 3,089Fund votes
  • June 24, 2025Main meeting date

Results at a glance

Meeting of June 24, 2025: 6 items on RHYTHM PHARMACEUTICALS INC.’s Form 8-K, filed June 26, 2025: 1 approved · 5 passed (calculated).

Meeting of September 18, 2024: 6 items on RHYTHM PHARMACEUTICALS INC.’s Form 8-K, filed September 19, 2024: 1 approved · 5 passed (calculated).

Dissent

Significant dissent: 1 director (40.3% against); 1 say-on-pay vote (69.4% support); 1 equity or compensation plan (37.2% against).

Notable dissent: 3 directors (13.6%, 12.7%, 12.5% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Activist investors: Ra Capital Management, L.P. (13F, 9.6%, as of September 30, 2026)

Explore RHYTHM PHARMACEUTICALS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by RHYTHM PHARMACEUTICALS INC.

These tallies are RHYTHM PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 26, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX. RHYTHM PHARMACEUTICALS INC. reported 2 meetings in this season; each is tabulated separately below, with its own filing.

RHYTHM PHARMACEUTICALS INC. — official shareholder meeting results, meeting held June 24, 2025 (Form 8-K, filed June 26, 2025)
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Jennifer Good 55,565,432---- 3,393,2571,759,938 94%Passed (calculated)—
Elect Director: Edward T. Mathers 35,169,176---- 23,789,5131,759,938 60%Passed (calculated)—
2. Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2025 60,554,577158,1235,927 --0 99.7%Passed (calculated)—
3. Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers 40,890,84618,057,76310,080 --1,759,938 69%Passed (calculated)—
4. Approval of an amendment to our Amended and Restated Certificate of Incorporation to provide for exculpation of officers from breaches of fiduciary duty to the fullest extent permitted by the General Corporation Law of the State of Delaware (the "Officer Ex 55,466,4403,483,9358,314 --1,759,938 94%Passed (calculated)—
5. Approval of an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting to approve the Officer Exculpation Amendment 52,278,2196,673,4707,000 --1,759,938 89%Approved—

Source: RHYTHM PHARMACEUTICALS INC., Form 8-K, filed with the SEC on June 26, 2025 — read the filing on EDGAR.

RHYTHM PHARMACEUTICALS INC. — official shareholder meeting results, meeting held September 18, 2024 (Form 8-K, filed September 19, 2024)
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Stuart A. Arbuckle 45,585,464---- 6,530,7011,829,832 87%Passed (calculated)—
Elect Director: Christophe R. Jean 45,017,705---- 7,098,4601,829,832 86%Passed (calculated)—
Elect Director: Lynn A. Tetrault 45,485,067---- 6,631,0981,829,832 87%Passed (calculated)—
2. Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024 53,844,43069,53932,028 --0 99.9%Passed (calculated)—
3. Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers 50,612,2891,487,31716,559 --1,829,832 97%Passed (calculated)—
4. Reapproval of the Rhythm Pharmaceuticals, Inc. 2017 Equity Incentive Plan 32,739,79619,359,37916,990 --1,829,832 63%Approved—

Source: RHYTHM PHARMACEUTICALS INC., Form 8-K, filed with the SEC on September 19, 2024 — read the filing on EDGAR.

How asset managers voted at the RHYTHM PHARMACEUTICALS INC. 2024-2025 meetings

292 asset managers disclosed a vote on at least one RHYTHM PHARMACEUTICALS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Edward T. Mathers

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Meeting held June 24, 2025.

Combines 4 wordings of this item as funds reported it.

60% Majority: yes · of votes cast

FOR 60%WITHHELD
FOR: 35,169,176WITHHELD: 23,789,513
Details: description as filed, official tally, votes by 85 asset managers

Description as filed by funds: Election of the Class II directors, each to serve for a three year term until the 2028 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified: Edward T. Mathers

RHYTHM PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Edward T. Mathers”): 35,169,176 for, 23,789,513 withheld, per its Form 8-K filed June 26, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 60% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 85 asset managers below reported 11,081,067 for, 7,846,061 withheld, 4,351,574 abstained.

FORABSTAINWITHHOLD
FOR: 11,081,067ABSTAIN: 4,351,574WITHHOLD: 7,846,061
Largest asset managers voting on “Election of the Class II directors, each to serve for a three year term until the 2028 Annual Meeting of Stock” at RHYTHM PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
PRIMECAP Odyssey Funds5,361,3090 00For
Vanguard3,354,9500 00For
BlackRock00 3,259,0150Abstain
Fidelity00 02,927,727Withhold
Federated Hermes1,655,5700 00For
T. Rowe Price00 0890,762Withhold
State Street2,0280 0716,484Withhold
ACAP Strategic Fund00 0502,832Withhold
Charles Schwab00 0454,523Withhold
Manager Directed Portfolios369,0240 00For
Putnam00 0361,067Withhold
Loomis Sayles00 342,7250Abstain
HARBOR FUNDS00 314,9510Abstain
JANUS INVESTMENT FUND255,6430 00For
DRIEHAUS MUTUAL FUNDS00 0248,237Withhold
Equitable00 0171,898Withhold
Invesco00 0162,016Withhold
JPMorgan00 159,0010Abstain
Advantage Advisers Xanthus Fund, L.L.C.00 0146,151Withhold
TIAA00 0140,826Withhold
Brighthouse00 0112,023Withhold
QUANTITATIVE MASTER SERIES LLC00 94,1790Abstain
Aberdeen00 079,956Withhold
First Trust00 074,297Withhold
Russell Investments00 057,173Withhold

Showing the 25 largest of 85 asset managers. All 85 are in the interactive database (link above).

Elect Director: Jennifer Good

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Meeting held June 24, 2025.

Combines 4 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%
FOR: 55,565,432WITHHELD: 3,393,257
Details: description as filed, official tally, votes by 85 asset managers

Description as filed by funds: Election of the Class II directors, each to serve for a three year term until the 2028 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified: Jennifer Good

RHYTHM PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Jennifer Good”): 55,565,432 for, 3,393,257 withheld, per its Form 8-K filed June 26, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 94% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 85 asset managers below reported 21,444,292 for, 1,115,265 withheld, 719,145 abstained.

FOR
FOR: 21,444,292ABSTAIN: 719,145WITHHOLD: 1,115,265
Largest asset managers voting on “Election of the Class II directors, each to serve for a three year term until the 2028 Annual Meeting of Stock” at RHYTHM PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
PRIMECAP Odyssey Funds5,361,3090 00For
Vanguard3,354,9500 00For
BlackRock3,259,0150 00For
Fidelity2,927,7270 00For
Federated Hermes1,655,5700 00For
T. Rowe Price890,7620 00For
State Street718,5120 00For
ACAP Strategic Fund502,8320 00For
Charles Schwab00 0454,523Withhold
Manager Directed Portfolios00 369,0240Abstain
Putnam00 0361,067Withhold
Loomis Sayles00 342,7250Abstain
HARBOR FUNDS314,9510 00For
JANUS INVESTMENT FUND255,6430 00For
DRIEHAUS MUTUAL FUNDS248,2370 00For
Equitable111,6280 060,270Mixed
Invesco162,0160 00For
JPMorgan159,0010 00For
Advantage Advisers Xanthus Fund, L.L.C.146,1510 00For
TIAA140,8260 00For
Brighthouse47,8030 064,220Mixed
QUANTITATIVE MASTER SERIES LLC94,1790 00For
Aberdeen79,9560 00For
First Trust74,2970 00For
Russell Investments00 057,173Withhold

Showing the 25 largest of 85 asset managers. All 85 are in the interactive database (link above).

Elect Director: Christophe R. Jean

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Meeting held September 18, 2024.

Combines 4 wordings of this item as funds reported it.

86% Majority: yes · of votes cast

FOR 86%
FOR: 45,017,705WITHHELD: 7,098,460
Details: description as filed, official tally, votes by 75 asset managers

Description as filed by funds: Election of the Class I directors, each to serve for a three year term until the 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified: Christophe R. Jean

RHYTHM PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Christophe R. Jean”): 45,017,705 for, 7,098,460 withheld, per its Form 8-K filed September 19, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 86% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 75 asset managers below reported 19,663,318 for, 1,619,286 withheld, 47,993 abstained.

FOR
FOR: 19,663,318ABSTAIN: 47,993WITHHOLD: 1,619,286
Largest asset managers voting on “Election of the Class I directors, each to serve for a three year term until the 2027 Annual Meeting of Stockh” at RHYTHM PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
PRIMECAP Odyssey Funds6,960,3120 00For
BlackRock3,355,3960 00For
Vanguard3,217,3180 00For
Federated Hermes1,660,7800 00For
Fidelity1,111,5500 08,627For
State Street656,0030 0794For
ACAP Strategic Fund00 0490,138Withhold
Charles Schwab430,0470 00For
T. Rowe Price392,6390 00For
JANUS INVESTMENT FUND287,7240 00For
Loomis Sayles245,2810 00For
Putnam00 0215,035Withhold
Manager Directed Portfolios207,3610 00For
Artisan171,2390 00For
Invesco167,6000 00For
Equitable105,6470 059,570Mixed
DRIEHAUS MUTUAL FUNDS00 0158,419Withhold
TIAA146,2700 00For
Advantage Advisers Xanthus Fund, L.L.C.00 0146,200Withhold
Aberdeen00 0112,804Withhold
Brighthouse76,8560 013,635Mixed
First Trust00 070,091Withhold
Legg Mason59,6000 04,471Mixed
QUANTITATIVE MASTER SERIES LLC61,3240 00For
RBB FUND, INC.00 057,988Withhold

Showing the 25 largest of 75 asset managers. All 75 are in the interactive database (link above).

Elect Director: Lynn A. Tetrault

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Meeting held September 18, 2024.

Combines 4 wordings of this item as funds reported it.

87% Majority: yes · of votes cast

FOR 87%
FOR: 45,485,067WITHHELD: 6,631,098
Details: description as filed, official tally, votes by 75 asset managers

Description as filed by funds: Election of the Class I directors, each to serve for a three year term until the 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified: Lynn A. Tetrault

RHYTHM PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Lynn A. Tetrault”): 45,485,067 for, 6,631,098 withheld, per its Form 8-K filed September 19, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 87% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 75 asset managers below reported 19,701,291 for, 1,579,736 withheld, 49,570 abstained.

FOR
FOR: 19,701,291ABSTAIN: 49,570WITHHOLD: 1,579,736
Largest asset managers voting on “Election of the Class I directors, each to serve for a three year term until the 2027 Annual Meeting of Stockh” at RHYTHM PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
PRIMECAP Odyssey Funds6,960,3120 00For
BlackRock3,355,3960 00For
Vanguard3,217,3180 00For
Federated Hermes1,660,7800 00For
Fidelity1,111,5500 08,627For
State Street656,0030 0794For
ACAP Strategic Fund00 0490,138Withhold
Charles Schwab430,0470 00For
T. Rowe Price392,6390 00For
JANUS INVESTMENT FUND287,7240 00For
Loomis Sayles245,2810 00For
Putnam00 0215,035Withhold
Manager Directed Portfolios207,3610 00For
Artisan171,2390 00For
Invesco167,6000 00For
Equitable105,6470 059,570Mixed
DRIEHAUS MUTUAL FUNDS00 0158,419Withhold
TIAA146,2700 00For
Advantage Advisers Xanthus Fund, L.L.C.00 0146,200Withhold
Aberdeen00 0112,804Withhold
Brighthouse76,8560 013,635Mixed
First Trust00 070,091Withhold
Legg Mason59,6000 04,471Mixed
QUANTITATIVE MASTER SERIES LLC61,3240 00For
RBB FUND, INC.00 057,988Withhold

Showing the 25 largest of 75 asset managers. All 75 are in the interactive database (link above).

Elect Director: Stuart A. Arbuckle

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Meeting held September 18, 2024.

Combines 4 wordings of this item as funds reported it.

87% Majority: yes · of votes cast

FOR 87%
FOR: 45,585,464WITHHELD: 6,530,701
Details: description as filed, official tally, votes by 75 asset managers

Description as filed by funds: Election of the Class I directors, each to serve for a three year term until the 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified: Stuart A. Arbuckle

RHYTHM PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Stuart A. Arbuckle”): 45,585,464 for, 6,530,701 withheld, per its Form 8-K filed September 19, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 87% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 75 asset managers below reported 19,702,868 for, 1,579,736 withheld, 47,993 abstained.

FOR
FOR: 19,702,868ABSTAIN: 47,993WITHHOLD: 1,579,736
Largest asset managers voting on “Election of the Class I directors, each to serve for a three year term until the 2027 Annual Meeting of Stockh” at RHYTHM PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
PRIMECAP Odyssey Funds6,960,3120 00For
BlackRock3,355,3960 00For
Vanguard3,217,3180 00For
Federated Hermes1,660,7800 00For
Fidelity1,111,5500 08,627For
State Street656,0030 0794For
ACAP Strategic Fund00 0490,138Withhold
Charles Schwab430,0470 00For
T. Rowe Price392,6390 00For
JANUS INVESTMENT FUND287,7240 00For
Loomis Sayles245,2810 00For
Putnam00 0215,035Withhold
Manager Directed Portfolios207,3610 00For
Artisan171,2390 00For
Invesco167,6000 00For
Equitable105,6470 059,570Mixed
DRIEHAUS MUTUAL FUNDS00 0158,419Withhold
TIAA146,2700 00For
Advantage Advisers Xanthus Fund, L.L.C.00 0146,200Withhold
Aberdeen00 0112,804Withhold
Brighthouse76,8560 013,635Mixed
First Trust00 070,091Withhold
Legg Mason59,6000 04,471Mixed
QUANTITATIVE MASTER SERIES LLC61,3240 00For
RBB FUND, INC.00 057,988Withhold

Showing the 25 largest of 75 asset managers. All 75 are in the interactive database (link above).

Approval of an amendment to our Amended and Restated Certificate of Incorporation to provide for exculpation of…

Calculated outcomeCORPORATE GOVERNANCEPassed (calculated)

Meeting held June 24, 2025.

Combines 4 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%
FOR: 55,466,440AGAINST: 3,483,935
Details: description as filed, official tally, votes by 85 asset managers

Description as filed by funds: Approval of an amendment to our Amended and Restated Certificate of Incorporation to provide for exculpation of officers from breaches of fiduciary duty to the fullest extent permitted by the General Corporation Law of the State of Delaware (the "Officer Exculpation Proposal").

RHYTHM PHARMACEUTICALS INC.’s own tally for this item (“4. Approval of an amendment to our Amended and Restated Certificate of Incorporation to provide for exculpation of officers from breaches of fiduciary duty to the fullest extent permitted by the General Corporation Law o”): 55,466,440 for, 3,483,935 against, per its Form 8-K filed June 26, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 85 asset managers below reported 22,169,435 for, 1,104,496 against, 4,771 abstained.

FOR
FOR: 22,169,435AGAINST: 1,104,496ABSTAIN: 4,771
Largest asset managers voting on “Approval of an amendment to our Amended and Restated Certificate of Incorporation to provide for exculpation o” at RHYTHM PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
PRIMECAP Odyssey Funds5,361,3090 00For
Vanguard3,354,9500 00For
BlackRock3,259,0150 00For
Fidelity2,927,7270 00For
Federated Hermes1,655,5700 00For
T. Rowe Price890,7620 00For
State Street718,079433 00For
ACAP Strategic Fund502,8320 00For
Charles Schwab454,5230 00For
Manager Directed Portfolios0369,024 00Against
Putnam361,0670 00For
Loomis Sayles0342,725 00Against
HARBOR FUNDS314,9510 00For
JANUS INVESTMENT FUND255,6430 00For
DRIEHAUS MUTUAL FUNDS248,2370 00For
Equitable171,8980 00For
Invesco162,0160 00For
JPMorgan0159,001 00Against
Advantage Advisers Xanthus Fund, L.L.C.146,1510 00For
TIAA140,8260 00For
Brighthouse47,80364,220 00Mixed
QUANTITATIVE MASTER SERIES LLC94,1790 00For
Aberdeen79,9560 00For
First Trust74,2970 00For
Russell Investments057,173 00Against

Showing the 25 largest of 85 asset managers. All 85 are in the interactive database (link above).

Approval of an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not…

Official resultCORPORATE GOVERNANCEReported outcome: Approved

Meeting held June 24, 2025.

89% Approved · of votes cast

FOR 89%
FOR: 52,278,219AGAINST: 6,673,470
Details: description as filed, official tally, votes by 83 asset managers

Description as filed by funds: APPROVAL OF AN ADJOURNMENT OF THE ANNUAL MEETING, IF NECESSARY, TO SOLICIT ADDITIONAL PROXIES IF THERE ARE NOT SUFFICIENT VOTES AT THE TIME OF THE ANNUAL MEETING TO APPROVE THE OFFICER EXCULPATION AMENDMENT.

RHYTHM PHARMACEUTICALS INC.’s own tally for this item (“5. Approval of an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting to approve the Officer Exculpation Amendment”): 52,278,219 for, 6,673,470 against — passed, per its Form 8-K filed June 26, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 5: Approval of an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting to approve the Officer Exculpation Amendment”
Support: 89% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 83 asset managers below reported 20,150,059 for, 3,121,568 against, 4,771 abstained.

FOR
FOR: 20,150,059AGAINST: 3,121,568ABSTAIN: 4,771
Largest asset managers voting on “APPROVAL OF AN ADJOURNMENT OF THE ANNUAL MEETING, IF NECESSARY, TO SOLICIT ADDITIONAL PROXIES IF THERE ARE NOT” at RHYTHM PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
PRIMECAP Odyssey Funds5,361,3090 00For
Vanguard3,354,9500 00For
BlackRock3,259,0150 00For
Fidelity2,927,7270 00For
Federated Hermes1,655,5700 00For
T. Rowe Price0890,762 00Against
State Street12,327706,185 00Against
ACAP Strategic Fund502,8320 00For
Charles Schwab0454,523 00Against
Manager Directed Portfolios0369,024 00Against
Putnam361,0670 00For
Loomis Sayles0342,725 00Against
HARBOR FUNDS314,9510 00For
JANUS INVESTMENT FUND255,6430 00For
DRIEHAUS MUTUAL FUNDS248,2370 00For
Equitable167,0204,878 00For
Invesco162,0160 00For
JPMorgan159,0010 00For
Advantage Advisers Xanthus Fund, L.L.C.146,1510 00For
TIAA140,8260 00For
Brighthouse19,68192,342 00Mixed
QUANTITATIVE MASTER SERIES LLC94,1790 00For
Aberdeen79,9560 00For
First Trust74,2970 00For
Russell Investments057,173 00Against

Showing the 25 largest of 83 asset managers. All 83 are in the interactive database (link above).

Reapproval of the Rhythm Pharmaceuticals, Inc. 2017 Equity Incentive Plan

Official resultFund totals may overlapCOMPENSATIONReported outcome: Approved

Meeting held September 18, 2024.

Combines 2 wordings of this item as funds reported it.

63% Approved · of votes cast

FOR 63%AGAINST
FOR: 32,739,796AGAINST: 19,359,379
Details: description as filed, official tally, votes by 77 asset managers

Description as filed by funds: Reapproval of the Rhythm Pharmaceuticals, Inc. 2017 Equity Incentive Plan.

RHYTHM PHARMACEUTICALS INC.’s own tally for this item (“4. Reapproval of the Rhythm Pharmaceuticals, Inc. 2017 Equity Incentive Plan”): 32,739,796 for, 19,359,379 against — passed, per its Form 8-K filed September 19, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Item 4 - Reapproval of the Rhythm Pharmaceuticals, Inc. 2017 Equity Incentive Plan.”
Support: 63% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 74 asset managers voting on “Reapproval of the Rhythm Pharmaceuticals, Inc. 2017 Equity Incentive Plan.” at RHYTHM PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
PRIMECAP Odyssey Funds6,960,3120 00For
BlackRock03,355,396 00Against
Vanguard3,217,3180 00For
Federated Hermes1,660,7800 00For
Fidelity01,120,177 00Against
State Street644656,153 00Against
ACAP Strategic Fund0490,138 00Against
Charles Schwab0430,047 00Against
T. Rowe Price0392,639 00Against
JANUS INVESTMENT FUND287,7240 00For
Loomis Sayles0245,281 00Against
Putnam0215,035 00Against
Manager Directed Portfolios0207,361 00Against
Artisan0171,239 00Against
Invesco0167,600 00Against
Equitable10,882154,335 00Mixed
DRIEHAUS MUTUAL FUNDS0158,419 00Against
TIAA0146,270 00Against
Advantage Advisers Xanthus Fund, L.L.C.0146,200 00Against
Aberdeen0112,804 00Against
Brighthouse090,491 00Against
First Trust070,091 00Against
Legg Mason064,071 00Against
QUANTITATIVE MASTER SERIES LLC061,324 00Against
RBB FUND, INC.057,988 00Against

Fund voting reports, all 74 managers: 12,203,550 for, 9,117,845 against, 8,457 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 3 asset managers voting on “Reapproval of the Rhythm Pharmaceuticals, Inc. 2017 Equity Incentive Plan.” at RHYTHM PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
NEA Management Company, LLC2,909,9560 00For
ALGERT GLOBAL LLC058,919 00Against
UNITED CAPITAL FINANCIAL ADVISORS, LLC0147 00Against

Institutional-manager reports, all 3 managers: 2,909,956 for, 59,066 against.

Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers

Calculated outcomeFund totals may overlapSECTION 14A SAY-ON-PAY VOTESPassed (calculated)

Meeting held June 24, 2025.

Combines 8 wordings of this item as funds reported it.

69% Majority: yes · of votes cast

FOR 69%AGAINST
FOR: 40,890,846AGAINST: 18,057,763
Details: description as filed, official tally, votes by 259 asset managers

Description as filed by funds: Approval, on an advisory (non- binding) basis, of the compensation of the named executive officers of the Company.

RHYTHM PHARMACEUTICALS INC.’s own tally for this item (“3. Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers”): 40,890,846 for, 18,057,763 against, per its Form 8-K filed June 26, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 69% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 84 asset managers voting on “Approval, on an advisory (non- binding) basis, of the compensation of the named executive officers of the Comp” at RHYTHM PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
PRIMECAP Odyssey Funds5,361,3090 00For
Vanguard3,354,9500 00For
BlackRock03,259,015 00Against
Fidelity1,753,3001,174,427 00Mixed
Federated Hermes1,655,5700 00For
T. Rowe Price883,4620 00For
State Street708,17110,341 00For
ACAP Strategic Fund0502,832 00Against
Charles Schwab0454,523 00Against
Manager Directed Portfolios0369,024 00Against
Putnam0361,067 00Against
Loomis Sayles0342,725 00Against
HARBOR FUNDS0314,951 00Against
JANUS INVESTMENT FUND255,6430 00For
DRIEHAUS MUTUAL FUNDS248,2370 00For
Equitable24,326147,572 00Mixed
Invesco0162,016 00Against
JPMorgan159,0010 00For
Advantage Advisers Xanthus Fund, L.L.C.0146,151 00Against
TIAA115,4120 00For
Brighthouse28,12283,901 00Mixed
QUANTITATIVE MASTER SERIES LLC094,179 00Against
Aberdeen79,9560 00For
First Trust074,297 00Against
Russell Investments057,173 00Against

Fund voting reports, all 84 managers: 15,108,156 for, 8,131,502 against, 4,771 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 203 asset managers voting on “Approval, on an advisory (non- binding) basis, of the compensation of the named executive officers of the Comp” at RHYTHM PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
PRIMECAP MANAGEMENT CO/CA/5,636,6970 00For
BAKER BROS. ADVISORS LP5,604,4830 00For
RA CAPITAL MANAGEMENT, L.P.5,491,1230 00For
NEA Management Company, LLC2,911,3490 00For
BlackRock27,6882,708,049 00Against
PERCEPTIVE ADVISORS LLC1,990,9670 00For
Fidelity1,811,2710 00For
State Street1,750,63325,781 00For
Federated Hermes1,659,7370 00For
Janus Henderson1,580,93936,718 00For
GEODE CAPITAL MANAGEMENT, LLC01,299,568 00Against
T. Rowe Price1,228,2450 00For
WESTFIELD CAPITAL MANAGEMENT CO LP01,101,032 00Against
Checkpoint Capital L.P.1,043,7750 00For
DRIEHAUS CAPITAL MANAGEMENT LLC839,7320 00For
Hood River Capital Management LLC0649,160 00Against
MARSHALL WACE, LLP0633,696 00Against
Loomis Sayles0586,960 00Against
Putnam0479,059 00Against
Opaleye Management Inc.475,0000 00For
Northern Trust446,70912,450 00For
Charles Schwab0454,692 00Against
Point720331,189 00Against
PICTET ASSET MANAGEMENT SA0326,948 00Against
Rock Springs Capital Management LP312,0960 00For

Institutional-manager reports, all 203 managers: 34,379,582 for, 11,588,006 against, 891 abstained, 252 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers

Calculated outcomeFund totals may overlapSECTION 14A SAY-ON-PAY VOTESPassed (calculated)

Meeting held September 18, 2024.

Combines 7 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 50,612,289AGAINST: 1,487,317
Details: description as filed, official tally, votes by 218 asset managers

Description as filed by funds: APPROVAL, ON AN ADVISORY (NON-BINDING) BASIS, OF THE COMPENSATION OF THE NAMED EXECUTIVE OFFICERS OF THE COMPANY.

RHYTHM PHARMACEUTICALS INC.’s own tally for this item (“3. Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers”): 50,612,289 for, 1,487,317 against, per its Form 8-K filed September 19, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 74 asset managers voting on “APPROVAL, ON AN ADVISORY (NON-BINDING) BASIS, OF THE COMPENSATION OF THE NAMED EXECUTIVE OFFICERS OF THE COMPA” at RHYTHM PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
PRIMECAP Odyssey Funds6,960,3120 00For
BlackRock3,355,3960 00For
Vanguard3,217,3180 00For
Federated Hermes1,660,7800 00For
Fidelity1,120,1770 00For
State Street656,7970 00For
ACAP Strategic Fund490,1380 00For
Charles Schwab430,0470 00For
T. Rowe Price392,6390 00For
JANUS INVESTMENT FUND287,7240 00For
Loomis Sayles245,2810 00For
Putnam215,0350 00For
Manager Directed Portfolios207,3610 00For
Artisan171,2390 00For
Invesco0167,600 00Against
Equitable165,2170 00For
DRIEHAUS MUTUAL FUNDS158,4190 00For
Advantage Advisers Xanthus Fund, L.L.C.146,2000 00For
Aberdeen112,8040 00For
TIAA99,7270 00For
Brighthouse90,4910 00For
First Trust70,0910 00For
Legg Mason64,0710 00For
QUANTITATIVE MASTER SERIES LLC61,3240 00For
RBB FUND, INC.57,9880 00For

Fund voting reports, all 74 managers: 21,078,387 for, 195,821 against, 8,457 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 169 asset managers voting on “APPROVAL, ON AN ADVISORY (NON-BINDING) BASIS, OF THE COMPENSATION OF THE NAMED EXECUTIVE OFFICERS OF THE COMPA” at RHYTHM PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
PRIMECAP MANAGEMENT CO/CA/7,305,7910 00For
BAKER BROS. ADVISORS LP6,398,3650 00For
RA CAPITAL MANAGEMENT, L.P.3,944,4900 00For
NEA Management Company, LLC2,909,9560 00For
Frazier Life Sciences Management, L.P.2,416,9520 00For
PERCEPTIVE ADVISORS LLC2,107,6810 00For
BlackRock1,741,1490 00For
State Street1,714,5840 00For
Federated Hermes1,660,7820 00For
Rock Springs Capital Management LP1,235,4900 00For
GEODE CAPITAL MANAGEMENT, LLC1,160,7550 00For
DRIEHAUS CAPITAL MANAGEMENT LLC754,3220 00For
ORBIMED ADVISORS LLC704,8420 00For
Commodore Capital LP700,0000 00For
Checkpoint Capital L.P.616,7150 00For
T. Rowe Price543,1740 00For
PICTET ASSET MANAGEMENT SA523,0480 00For
Opaleye Management Inc.505,0000 00For
Charles Schwab430,0570 00For
Putnam428,7280 00For
Northern Trust422,1770 00For
CANADA PENSION PLAN INVESTMENT BOARD417,0000 00For
Loomis Sayles415,2630 00For
Hood River Capital Management LLC374,9200 00For
Janus Henderson368,0110 00For

Institutional-manager reports, all 169 managers: 42,689,114 for, 1,112,804 against, 440 abstained, 128 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for…

Calculated outcomeAUDIT-RELATEDPassed (calculated)

Meeting held June 24, 2025.

Combines 2 wordings of this item as funds reported it.

99.7% Majority: yes · of votes cast

FOR 99.7%
FOR: 60,554,577AGAINST: 158,123
Details: description as filed, official tally, votes by 85 asset managers

Description as filed by funds: RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE COMPANY FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.

RHYTHM PHARMACEUTICALS INC.’s own tally for this item (“2. Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2025”): 60,554,577 for, 158,123 against, per its Form 8-K filed June 26, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 85 asset managers below reported 23,243,473 for, 30,458 against, 4,771 abstained.

FOR
FOR: 23,243,473AGAINST: 30,458ABSTAIN: 4,771
Largest asset managers voting on “RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR ” at RHYTHM PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
PRIMECAP Odyssey Funds5,361,3090 00For
Vanguard3,354,9500 00For
BlackRock3,259,0150 00For
Fidelity2,927,7270 00For
Federated Hermes1,655,5700 00For
T. Rowe Price890,7620 00For
State Street718,47141 00For
ACAP Strategic Fund502,8320 00For
Charles Schwab454,5230 00For
Manager Directed Portfolios369,0240 00For
Putnam361,0670 00For
Loomis Sayles342,7250 00For
HARBOR FUNDS314,9510 00For
JANUS INVESTMENT FUND255,6430 00For
DRIEHAUS MUTUAL FUNDS248,2370 00For
Equitable171,8980 00For
Invesco162,0160 00For
JPMorgan159,0010 00For
Advantage Advisers Xanthus Fund, L.L.C.146,1510 00For
TIAA140,8260 00For
Brighthouse112,0230 00For
QUANTITATIVE MASTER SERIES LLC94,1790 00For
Aberdeen79,9560 00For
First Trust74,2970 00For
Russell Investments57,1730 00For

Showing the 25 largest of 85 asset managers. All 85 are in the interactive database (link above).

Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for…

Calculated outcomeAUDIT-RELATEDPassed (calculated)

Meeting held September 18, 2024.

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 53,844,430AGAINST: 69,539
Details: description as filed, official tally, votes by 72 asset managers

Description as filed by funds: Ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2024.

RHYTHM PHARMACEUTICALS INC.’s own tally for this item (“2. Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024”): 53,844,430 for, 69,539 against, per its Form 8-K filed September 19, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 72 asset managers below reported 21,319,701 for, 91 against, 8,457 abstained.

FOR
FOR: 21,319,701AGAINST: 91ABSTAIN: 8,457
Largest asset managers voting on “Ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm for ” at RHYTHM PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
PRIMECAP Odyssey Funds6,960,3120 00For
BlackRock3,355,3960 00For
Vanguard3,217,3180 00For
Federated Hermes1,660,7800 00For
Fidelity1,120,1770 00For
State Street656,70691 00For
ACAP Strategic Fund490,1380 00For
Charles Schwab430,0470 00For
T. Rowe Price392,6390 00For
JANUS INVESTMENT FUND287,7240 00For
Loomis Sayles245,2810 00For
Putnam215,0350 00For
Manager Directed Portfolios207,3610 00For
Artisan171,2390 00For
Invesco167,6000 00For
Equitable165,2170 00For
DRIEHAUS MUTUAL FUNDS158,4190 00For
TIAA146,2700 00For
Advantage Advisers Xanthus Fund, L.L.C.146,2000 00For
Aberdeen112,8040 00For
Brighthouse90,4910 00For
First Trust70,0910 00For
Legg Mason64,0710 00For
QUANTITATIVE MASTER SERIES LLC61,3240 00For
RBB FUND, INC.57,9880 00For

Showing the 25 largest of 72 asset managers. All 72 are in the interactive database (link above).

Largest RHYTHM PHARMACEUTICALS INC. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 63,494,892 shares outstanding at the time of that meeting.

Fund voting reports: top RHYTHM PHARMACEUTICALS INC. shareholders by shares voted on “Approval, on an advisory (non- binding) basis, of the compensation of the named executive…”, 2024-2025
#Asset manager % of shares outstanding
1PRIMECAP Odyssey Funds 8.44%
2Vanguard 5.28%
3BlackRock 5.13%
4Fidelity 4.61%
5Federated Hermes 2.61%
6T. Rowe Price 1.39%
7State Street 1.13%
8ACAP Strategic Fund 0.79%
9Charles Schwab 0.72%
10Manager Directed Portfolios 0.58%
Institutional-manager reports: top RHYTHM PHARMACEUTICALS INC. shareholders by shares voted on “Approval, on an advisory (non- binding) basis, of the compensation of the named executive…”, 2024-2025
#Asset manager % of shares outstanding
1PRIMECAP MANAGEMENT CO/CA/ 8.88%
2BAKER BROS. ADVISORS LP 8.83%
3RA CAPITAL MANAGEMENT, L.P. 8.65%
4NEA Management Company, LLC 4.59%
5BlackRock 4.31%
6PERCEPTIVE ADVISORS LLC 3.14%
7Fidelity 2.85%
8State Street 2.80%
9Federated Hermes 2.61%
10Janus Henderson 2.55%

Reported RHYTHM PHARMACEUTICALS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

RHYTHM PHARMACEUTICALS INC. holdings and ownership disclosed for the 2024-2025 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
BlackRock6,854,755 10.80%Form 13F, quarter ended March 31, 2025
RA Capital Management, L.P.6,666,837 10.50%Schedule 13G, filed February 17, 2026
Baker Bros. Advisors LP5,604,483 8.83%Schedule 13G, filed May 15, 2025
Perceptive Advisors LLC3,519,626 5.54%Schedule 13G, filed May 15, 2026
PRIMECAP MANAGEMENT CO/CA/3,478,669 5.48%Schedule 13G, filed February 12, 2026
Vanguard Group3,444,926 5.43%Form 13F, quarter ended March 31, 2025
State Street1,970,733 3.10%Form 13F, quarter ended March 31, 2025
FMR (Fidelity)1,688,375 2.66%Form 13F, quarter ended March 31, 2025
Goldman Sachs1,637,908 2.58%Form 13F, quarter ended March 31, 2025
T. Rowe Price1,199,053 1.89%Form 13F, quarter ended March 31, 2025

Percentages above are of 63,494,892 shares outstanding, as reported by RHYTHM PHARMACEUTICALS INC. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At RHYTHM PHARMACEUTICALS INC.'s 2 shareholder meetings in the 2024-2025 proxy season (held September 18, 2024 and June 24, 2025), 292 asset managers reported votes on at least one of its 12 ballot items in their SEC Form N-PX filings, covering 3,089 separate fund positions. On the most widely held item of the season, voted at the meeting held June 24, 2025 — Approval, on an advisory (non- binding) basis, of the compensation of the named executive… — FOR was 69% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: RHYTHM PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 26, 2025.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from RHYTHM PHARMACEUTICALS INC.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

RHYTHM PHARMACEUTICALS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.

Cite this page

Proxy Votes Now, “RHYTHM PHARMACEUTICALS (RYTM) 2024-2025 Annual Meetings: Vote Results”, https://proxyvotesnow.com/company/rhythm-pharmaceuticals-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.